Navigation Links
Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY
Date:3/28/2012

/>Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS
Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacolo
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
2. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
3. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
5. Regado Biosciences Establishes Medical Advisory Board
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
8. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
11. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015  US-Australian drug discovery company, Novogen ... it received a letter from NASDAQ informing it that ... 5550(b) (Listing Rule). In November 2014, ... the Company to submit a plan to regain compliance ... minimum of $2,500,000 in stockholders, equity as of June ...
(Date:4/28/2015)... 28, 2015 IMS is releasing ... it to the web and provide greater accessibility ... friendly reporting metrics increase data warehouse’s utility; plus, ... recall and access “on-the-go” makes data analysis even ... client feedback to assist in repository analytics and ...
(Date:4/28/2015)... 2015 Spartan Bioscience today announced that ... selected by the Ottawa Chamber of Commerce as one ... was selected from over 240 applicants based on his ... to Spartan, Dr. Lem founded Plexagen Diagnostics, and also ... holds a Medical Degree from the University of Ottawa, ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
Breaking Biology Technology:Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4
... THOR ), a world leader in device-based mechanical,circulatory ... announced that it will report its operating results for ... on Thursday, October 30., The company will hold ... activities to all interested parties at 1:30 p.m.,Pacific Daylight ...
... QUEBEC CITY, Oct. 24 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... Stock Market, notifying AEterna Zentaris that during the ... the bid price of the,Company,s common shares had ...
... Fastest-Growing Companies, TUSTIN, Calif., Oct. 24 ... a vertically integrated pharmaceutical company with major,operations in ... been recognized by,Deloitte LLP as the 6th fastest ... Technology Fast 50 Program., This nationally-recognized program ...
Cached Biology Technology:Thoratec Schedules Third Quarter 2008 Conference Call, Webcast 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3AMDL, Inc. Named to Deloitte LLC Technology Fast 50 2AMDL, Inc. Named to Deloitte LLC Technology Fast 50 3AMDL, Inc. Named to Deloitte LLC Technology Fast 50 4
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... study of apex predators in the Pacific Ocean found ... previously thought, unknown relationships between other species, and the ... of these sea creatures. The field program, dubbed ... at 23 species from 2000-09 and included researchers from ...
... WI, JUNE 22, 2011 -- Vinyl chloride is a ... anaerobic conditions. These solvents are used in many industrial ... most encountered groundwater pollutants in industrialized countries. Groundwater is ... to determine if vinyl chloride can be further degraded ...
... by psychologists at the University of Toronto and Tufts University ... sexual orientation when looking at his face, when she is ... thoughts or a mating goal heightens a woman,s ability to ... not apparent when a woman is judging another female,s orientation," ...
Cached Biology News:Decade-long study of Pacific predators shows importance of biological 'hotspots' 2Decade-long study of Pacific predators shows importance of biological 'hotspots' 3Psychologists find link between ovulation and women's ability to identify heterosexual men 2